The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

Hvidovre University Hospital10 enrolled

Overview

Aim: To investigate the glucagonostatic effect of glucagon-like peptide-1 (GLP-1) independent of the gastric emptying rate.

Aim: To investigate the glucagonostatic effects of glucagon-like peptide-1 (GLP-1) during prolonged and intermittent stimulation of the GLP-1 receptor independent of the gastric emptying rate. Glucagon concentrations will be measured following a liquid meal administered in duodenum at baseline and after exenatide, and liraglutide treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Type 1 Diabetes

Interventions

LiraglutideDRUG

ExenatideDRUG

Liquid meal testPROCEDURE

No drug (Baseline day)OTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 1 Diabetes * \>18 years * No residual beta-cell function (stimulated C-peptide \< 60 pmol) Exclusion Criteria: * Pancreatitis * gastroparesis * history of alcohol and/or drug abuse * pregnancy and lactation * other medical or psychological condition that made the patient unsuitable for study participation according to the investigators´ assessment * contraindications to gastroscopy * cancer (unless in complete remission \> five years)

Outcomes

Primary Outcomes

Glucagon concentration (postprandial)

glucagon area under the curve (AUC) (0-240 minutes) and baseline to peak increments will be calculated

Time frame: 4 hours

Secondary Outcomes

Postprandial glucose concentrations

glucose AUC (0-240 minutes) and baseline to peak increments will be calculated

Time frame: 4 hours

glucagon-like peptide-1 (GLP-1)

GLP-1 AUC (0-240 minutes) and baseline to peak increments will be calculated

Time frame: 4 hours

glucagon-like peptide-2 (GLP-2)

GLP-2 AUC (0-240 minutes) and baseline to peak increments will be calculated

Time frame: 4 hours

glucose-dependent insulinotropic polypeptide (GIP)

GIP AUC (0-240 minutes) and baseline to peak increments will be calculated

Time frame: 4 hours

Cholecystokinin (CCK)

CCKAUC (0-240 minutes) and baseline to peak increments will be calculated

Time frame: 4 hours

Peptide YY (PYY)

PYY AUC (0-240 minutes) and baseline to peak increments will be calculated

Time frame: 4 hours

Ghrelin

Ghrelin AUC (0-240 minutes) and baseline to peak increments will be calculated

Time frame: 4 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.